Routine intravascular ultrasound guidance of percutaneous coronary intervention A critical reappraisal by Orford, James L et al.
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outine Intravascular Ultrasound
uidance of Percutaneous Coronary Intervention
Critical Reappraisal
ames L. Orford, MBCHB, MPH, FESC, FACC, Amir Lerman, MD, FACC,
avid R. Holmes, MD, FACC
ochester, Minnesota
Intravascular ultrasound (IVUS) has played an integral role in the evolution of interventional
cardiology. However, routine IVUS guidance of coronary stent implantation is not supported
by a critical reappraisal of the available evidence. Although there is a trend toward a benefit
with respect to target lumen revascularization favoring IVUS-guided coronary stent implan-
tation, it is likely that this effect is driven by improved outcomes in small vessels, long
coronary stenoses, and possibly saphenous vein graft interventions. No consistent trend in the
incidence of death or myocardial infarction is apparent. Furthermore, the safety, efficacy, and
effectiveness of IVUS should be taken into account when considering the goals, risks, benefits,
and alternatives to such a treatment strategy. (J Am Coll Cardiol 2004;43:1335–42) © 2004
by the American College of Cardiology Foundationi
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intravascular ultrasound (IVUS) has played a critical role in
nderstanding the pathophysiology of coronary atheroscle-
osis and has facilitated the refinement of diagnostic and
herapeutic strategies. In vitro and in vivo observations have
ighlighted discrepancies between contrast angiography (a
wo-dimensionalsilhouette)andIVUS(cross-sectionaltomo-
raphic perspective and direct visualization of the vessel
all) and have led to a reappraisal of the relative strengths
nd weaknesses of contrast “luminology” (1). Specifically,
nsights into the mechanisms of percutaneous coronary
ntervention (PCI), as well as identification of the compli-
ations of the various approaches to percutaneous revascu-
arization, including acute and subacute vessel closure and
estenosis, have facilitated the refinement of these treatment
trategies. However, the role of IVUS guidance of PCI in
he contemporary era of routine coronary stent implantation
emains controversial and is subject to continuing debate.
his review outlines the evidence in support of routine
VUS guidance of coronary implantation and places it in the
ontext of contemporary clinical practice.
VUS AND CONTEMPORARY STENT TECHNIQUES
arly in vivo applications of IVUS. Cross-sectional IVUS
maging before and after balloon angioplasty has demon-
trated the anatomic boundaries of the intima, media, and
dventitia and has characterized the morphology of ather-
matous plaque (2,3). Furthermore, qualitative characteris-
ics of injury from balloon dilation, atherectomy, and stent
mplantation, including plaque disruption, dissection, and
From the Department of Cardiovascular Diseases and Internal Medicine, Mayo
linic, Rochester, Minnesota.
Manuscript received November 11, 2003; revised manuscript received December 8,i003, accepted December 9, 2003.ntimal flaps, have been defined and correlated with angio-
raphic, procedural, and clinical outcomes (4–8).
efinement of coronary stent technique and periproce-
ural drug treatment. After presentation and publication
f the BElgium NEtherlands Stent (BENESTENT) and
Tent REStenosis Study (STRESS) trials, routine coronary
tent implantation became increasingly popular (9,10).
owever, the incidence of subacute closure (stent throm-
osis) and major bleeding, due to the intensive anticoagu-
ation regimen, was unacceptable and limited the initial
linical applicability of IVUS. High-pressure stent deploy-
ent with IVUS guidance, as well as treatment with dual
ntiplatelet therapy (aspirin and ticlopidine), in preference
o systemic anticoagulation, established the safety and
fficacy of this alternative treatment strategy and expanded
he role of routine elective coronary stent implantation in
linical practice (11). Subsequently, similar results with this
trategy (high-pressure stent deployment and dual anti-
latelet therapy) were also achieved without IVUS guidance
12,13).
n-stent restenosis. Intravascular ultrasound has also
layed an important role in establishing the mechanisms of
n-stent restenosis. Restenosis after balloon angioplasty is
argely driven by concentric geometric remodeling, with
eointimal hyperplasia playing a lesser role; however, in-
tent restenosis is almost exclusively the consequence of
xuberant neointimal proliferation (14). In a serial ultra-
ound study of the patterns and mechanisms of in-stent
estenosis, late lumen loss within stents correlated strongly
ith tissue growth (neointimal tissue accumulation, r 
.975, p  0.001), but only weakly with stent recoil (r 
.2, p  0.001) (15). These in vivo IVUS observations were
nstrumental in the development of strategies to treat
n-stent restenosis, including intracoronary brachytherapy,
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IVUS Guidance of PCI April 21, 2004:1335–42ut most importantly they led to the development of
rug-eluting stents (DES), which appear to have dramati-
ally reduced neointimal proliferation and the incidence of
n-stent restenosis and may also replace intracoronary
rachytherapy as the preferred treatment for in-stent reste-
osis (16).
PTIMIZING THE RESULTS
F BALLOON ANGIOPLASTY:
HE SIPS STUDY AND THE BEST TRIAL
he IVUS-guided optimization of balloon angioplasty re-
ults (with provisional stenting) has also been investigated as
n alternative to routine stenting. The Strategy for Intra-
oronary ultrasound-guided PTCA and Stenting (SIPS) trial
andomized 269 patients to IVUS-guided or angiography-
uided balloon angioplasty with provisional stent implanta-
ion (17). Approximately 50% of patients in each group
eceived a stent at the time of the index procedure. Acute
ain was greater in the IVUS-guided group than in the
ngiography-guided group, but angiographic six-month
ollow-up revealed no difference in the primary end point of
inimum lumen diameter (MLD) or the secondary end
oints of binary restenosis rate and short-term or two-year
ajor adverse cardiac events (death, myocardial infarction
MI], or target lumen revascularization [TLR]). However,
linical follow-up (602  307 days) showed a significant
ecrease in clinically driven TLR in the IVUS group
ompared with the angiography group (17% vs. 29%, p 
.02).
The Balloon Equivalent to STent (BEST) study random-
zed 254 patients to either “aggressive” IVUS-guided bal-
oon angioplasty (with provisional stenting) or routine
ngiography-guided stent implantation (18). Approximately
4% of patients in the balloon angioplasty group required
djunctive stent implantation. At six months, 20 of 119
atients in the aggressive balloon angioplasty group and 21
f 116 patients in the routine stent implantation group had
estenosis, fulfilling the prespecified criteria for noninferi-
rity. Similarly, there were no statistically significant differ-
nces in the MLD or lumen cross-sectional area at six
onths or one-year clinical event rates.
The results of these two studies suggest that IVUS-
uided balloon angioplasty may be an acceptable alternative
o routine stenting (feasible, safe, and noninferior), but this
Abbreviations and Acronyms
DES  drug-eluting stent(s)
FFR  fractional flow reserve
IVUS  intravascular ultrasound
MI  myocardial infarction
MLD  minimum lumen diameter
PCI  percutaneous coronary intervention
TLR  target lumen revascularization
TVR  target vessel revascularizationpproach is certainly more time-consuming and requires qeticulous attention to detail and expertise in IVUS image
cquisition and interpretation. Furthermore, it is apparent
rom both these studies that the crossover rate is high, with
50% of patients requiring adjunctive stent implantation,
egating much of the anticipated cost-savings, particularly
n the contemporary era of falling prices of bare-metal
tents. The realities of clinical practice have therefore
esulted in widespread adoption of a strategy of routine stent
mplantation in preference to balloon angioplasty with
rovisional stent implantation (19).
OUTINE IVUS-GUIDED CORONARY
TENT IMPLANTATION: THE EVIDENCE
everal studies have demonstrated that IVUS is better than
ontrast angiography at defining post-deployment stent
imensions, confirming complete stent apposition, and
xcluding edge dissections—all important procedural vari-
bles that may predispose to both early and late complica-
ions, including in-stent restenosis (Table 1). Specifically,
everal small, single-center studies have identified IVUS
easurement of minimum stent area as the most powerful
redictor of long-term patency and clinical outcomes
20,21). However, it has been more difficult to prove this
utative clinical benefit utilizing more rigorous research
ethodology.
bservational and case-control studies: MUSIC, CRUISE,
nd others. The Multicenter Ultrasound Stenting In Cor-
naries (MUSIC) study established the safety and feasibility
f IVUS-guided stent implantation (22). A total of 161
atients were prospectively enrolled, 155 of whom under-
ent an IVUS examination. During the follow-up period
198  38 days), one patient (0.6%) suffered a Q-wave MI,
ne patient (0.6%) underwent bypass surgery, and seven
atients (4.5%) had repeat target lesion revascularization.
epeat angiography at six months was performed in 144
atients (92%), and angiographic restenosis (percent diam-
ter stenosis 50%) was documented in 12 patients (8.3%),
of whom required repeat PCI for stent thrombosis, so the
umulative angiographic restenosis rate was 9.7%. This
ompared favorably with historical controls and was re-
arded as proof of both the safety and feasibility of this
nterventional strategy.
Similarly, Fitzgerald et al. (23) enrolled 525 patients as a
ubset of the larger Stent Antithrombotic Regimen Study
STARS)—the Can Routine Ultrasound Influence Stent
xpansion (CRUISE) study. The use of IVUS was assigned
n a center-by-center basis; 16 of 45 STARS study centers
ere chosen for their experience with IVUS. In the seven
enters that performed only angiography-guided percutane-
us intervention, a blinded documentary IVUS study was
erformed on completion of the procedure. No optimal
VUS-determined stent criteria were prespecified. The
VUS group achieved a larger MLD by quantitative coro-
ary angiography and a larger minimum stent area by
uantitative coronary ultrasound, and these differences were
Table 1. Selected Studies of Intravascular Ultrasound– Versus Angiography-Guided Stent Implantation
Study
Patient Characteristics and
Study Design Primary End Point(s) Results Comments
CRUISE, Fitzgerald et al.,
2000 (23)
Case-control study, 525
patients, IVUS-guided vs.
angiography-guided stent
implantation
Postprocedural MLD by QCA
(diameter) and IVUS (area,
diameter)
MLD: 2.9  0.4 mm (IVUS) vs.
2.7  0.5 mm (angiography),
p  0.001; stent area: 7.78 
1.72 mm2 (IVUS) vs. 7.06 
2.13 mm2 (angiography), p 
0.001
TVR: 8.5% (IVUS) vs. 15.3% (angiography),
p  0.05; death: 0% (IVUS) vs. 1%
(angiography), p  NS; MI: 7% (IVUS)
vs. 6%, p  NS; death/MI/TVR: 12.6%
(IVUS) vs. 21.4% (angiography), p  0.09
Albiero et al., 1997 (24) Case-control study, 346
patients, IVUS-guided
(Milan) vs. angiography-
guided (Hamburg) stent
implantation
Dichotomous angiographic restenosis
(50% DS)
Restenosis, early phase: 9.2%
(IVUS) vs. 22.3%
(angiography), p  0.04;
restenosis, late phase: 22.7%
(IVUS) vs. 23.7%
(angiography), p  1.0
TLR: 7% (IVUS) vs. 11.7% (angiography), p
 0.17; high complication rate in early
(aggressive dilation) phase
RESIST, Schiele et al.,
1998 (26)
RCT, 155 after stenting
patients randomized to
group A (no further
dilation) and group B
(further dilation to
achieve IVUS criteria)
Six-month angiographic restenosis
(50% DS)
Angiographic restenosis: 28.8%
(group A) vs. 22.5% (group
B), p  0.25
18-month death/MI/TLR: 37% (group A)
vs. 25% (group B); OR 1.7, 95% CI 0.82–
3.63
AVID, Russo et al., 1999
(28)
RCT, 759 patients, IVUS-
guided vs. angiography-
guided stent implantation
“Clinical outcomes” Death: 0.3% (IVUS) vs. 0.6%
(angiography), p  0.39; MI:
8.9% (IVUS) vs. 5.2%
(angiography), p  0.07;
CABG: 3.1% (IVUS) vs. 3.2%
(angiography), p  0.92
TLR, small vessels (3.25 mm): 7.9%
(IVUS) vs. 14.6% (angiography), p 
0.04; TLR, SVG PCI: 5.7% (IVUS) vs.
20.4% (angiography) p  0.05
OPTICUS, Mudra et al.,
2001 (29)
RCT, 550 patients, IVUS-
guided vs. angiography-
guided stent implantation
Six-month angiographic restenosis
(50% DS), MLD, and %DS
Restenosis: 24.5% vs. 22.8%, p 
0.68; MLD: 1.95  0.72 mm
vs. 1.91  0.68 mm, p 
0.52; %DS: 34.8  20.6% vs.
36.8  19.6%, p  0.29
MACE: RR 1.07, 95% CI 0.75–1.52, p 
0.71; repeat PCI: RR 1.04, 95% CI 0.64–
1.67, p  0.87
TULIP, Oemrawsingh,
et al., 2003 (30)
RCT, 144 patients, stenosis
20 mm, stent diameter
3.0 mm; IVUS-guided
vs. angiography-guided
stent implantation
Six-month MLD and MACE
(death/MI/TLR)
MLD: 1.82  0.53 mm (IVUS)
vs. 1.51  0.71 mm
(angiography), p  0.042;
MACE: 23% (IVUS) vs. 27%
(angiography), p  0.026
Benefit in this specific patient population
(long stenoses in large vessels)
AVID  Angiography Versus Intravascular ultrasound Direct stent implantation; CABG  coronary artery bypass grafting; CI  confidence interval; CRUISE  Can Routine Ultrasound Influence Stent Expansion; DS  diameter
stenosis; IVUS  intravascular ultrasound; MACE  major adverse cardiac events; MI  myocardial infarction; MLD  minimum lumen diameter; OPTICUS  Optimization with ICUS to reduce stent restenosis; OR  odds ratio;
PCI  percutaneous coronary intervention; QCA  quantitative coronary angiography; RCT  randomized, controlled trial; RESIST  Restenosis after IVUS guided Stenting; RR  relative risk; SVG  saphenous vein graft; TLR
 target lumen revascularization; TULIP  Thrombocyte activity evaluation and effects of Ultrasound guidance in Long Intracoronary stent Placement; TVR  target vessel revascularization.
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IVUS Guidance of PCI April 21, 2004:1335–42ssociated with a 44% reduction in the rate of target vessel
evascularization (TVR) at nine months, but there was no
ifference in mortality or MI nor the secondary end
oint—a composite of death, MI, and TVR (Table 1).
Although part of a large, randomized, controlled trial
STARS), this analysis is an observational study with a
ontrol group drawn from the same study population
STARS) and is therefore subject to all of the limitations of
his study design. Most importantly, there were statistically
ignificant differences in the prevalence of single- and
ulti-vessel disease, and, despite statistical adjustment for
hese and other differences between the two groups, residual
onfounding cannot be excluded. The results of this trial
hould be regarded as provocative (hypothesis-generating),
ut certainly not definitive.
A similar case-control methodology was employed by
lbiero et al. (24), who matched 173 patients who were
reated with IVUS-guided Palmaz-Schatz stent implanta-
ion at a single center (Milan, Italy) with 173 patients
reated by angiography-guided Palmaz-Schatz stent im-
lantation at a different center (Hamburg, Germany). Im-
ediate and six-month angiographic results were retrospec-
ively compared, thus distinguishing an “early phase” from a
late phase”; this distinction was based on the more aggres-
ive dilation strategy with larger balloons and more de-
anding IVUS criteria for optimal stent expansion used in
ilan (IVUS center) in the early phase. In both phases, a
arger MLD immediately after stent implantation, as well as
fter six months, was achieved in the IVUS group compared
ith the angiography group. In the early phase, the dichot-
mous restenosis rate was lower in the IVUS group than in
he angiography group. However, a high procedural com-
lication rate and a high incidence of intracoronary vessel
upture were observed, possibly related to the use of over-
ized balloons (25). In the late phase, there was no difference
n the dichotomous restenosis rate between the groups, and
he incidence of repeat revascularization was not signifi-
antly different between the two groups. The results of this
nalysis were similarly provocative, suggesting a lower an-
iographic restenosis rate, but must be interpreted within
he context of the limitations of this study design.
andomized, controlled clinical trials: RESIST, AVID,
PTICUS, and TULIP. The REStenosis after IVUS-
uided STenting (RESIST) trial randomized 155 patients
o IVUS- or angiography-guided coronary stent implanta-
ion (26). At six months, there was a significant difference in
inimum cross-sectional lumen diameter, favoring the
VUS group, but no difference in MLD or angiographic
estenosis (Table 1). A second cost-effectiveness analysis
eported 18-month clinical outcomes: death, MI, or target
esion revascularization occurred more frequently in the
ngiography group than in the IVUS group (37% vs. 25%,
dds ratio 1.7, 95% confidence interval 0.82 to 3.63), but
his did not reach statistical significance (27).
Similarly, the Angiography Versus Intravascular ultra-
ound Direct stent placement (AVID) trial randomized 759 (atients who had undergone coronary stent implantation
ith an optimal angiographic result with IVUS-guided
irect coronary stent implantation or angiography-guided
irect coronary stent implantation (28). A blinded docu-
entary IVUS study was performed on completion of the
ngiography-guided procedure. The IVUS criteria for op-
imal stent deployment was percent area stenosis 10%,
bsence of dissection, and complete stent apposition. At 12
onths, there was no significant difference in the cumula-
ive rate of death, MI, or coronary artery bypass graft
urgery (Table 1). The results of a number of retrospective
ubgroup analyses have been presented, documenting lower
LR rates in patients with vessels 3.25 mm and saphe-
ous vein graft interventions, but these data are subject to all
f the limitations of such retrospective analyses and should
e interpreted with caution.
The OPTimization with ICUS to reduce stent restenosis
OPTICUS) trial randomized 550 patients to IVUS-guided
r angiography-guided coronary stent implantation (29). At
ix months, repeat angiography revealed no significant
ifferences between the groups with respect to the dichot-
mous restenosis rate, MLD, or percent diameter stenosis
Table 1). At 12 months, neither the incidence of major
dverse cardiac events nor repeat PCI was reduced in the
VUS group.
Finally, the Thrombocyte activity evaluation and effects
f Ultrasound guidance in Long Intracoronary stent Place-
ent (TULIP) trial randomized 144 patients with long
oronary lesions (20 mm) and a reference vessel diameter
3.0 mm to IVUS- or angiography-guided coronary stent
mplantation (30). This trial documented significant reduc-
ions in the incidence of both TLR alone and the combined
nd point of death, MI, and TLR (Table 1).
As documented, there is heterogeneity with respect to the
atient populations, study methodologies, and results of the
forementioned studies and trials of IVUS- versus
ngiography-guided PCI. Although there is a trend toward
benefit with respect to TLR favoring IVUS-guided
oronary stent implantation, it is likely that this effect is
riven by improved outcomes in small vessels, long coronary
tenoses, and possibly saphenous vein graft interventions, as
uggested by the retrospective subgroup analyses of the
VID trial and the results of the TULIP trial. No consis-
ent trend in the incidence of death or MI is apparent.
outine IVUS guidance of all elective procedures is not
upported by the results of the RESIST, AVID, and
PTICUS trials, although each is underpowered to detect
mall differences in the prespecified study end points.
urthermore, interpretation of both the RESIST and
VID trials is limited by incomplete reporting of the study
esign and methodology (AVID); patient, angiographic,
nd procedural characteristics (AVID); and procedural and
linical outcomes (AVID and RESIST).
fficacy versus effectiveness. The aforementioned clinical
rials provide us with evidence that addresses the efficacy
likelihood of beneficial outcome of a particular intervention
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April 21, 2004:1335–42 IVUS Guidance of PCInder optimal or ideal experimental conditions) of IVUS-
uided stent implantation, but they do not address the issue
f effectiveness (likelihood of beneficial outcome of a par-
icular intervention under usual and routine conditions).
he widespread clinical application and expected effective-
ess of IVUS-guided coronary stent implantation is likely to
e limited by a number of factors, including the cost of the
ltrasound catheter, the additional time to perform serial
VUS examinations, and the availability of appropriately
rained personnel capable of accurately acquiring and inter-
reting the images. It may also prove difficult to advance the
ltrasound catheter through a deployed stent, and there are
solated reports of stent damage attributable to the ultra-
ound catheter (31). Finally, although generally regarded as
safe procedure, IVUS is associated with clinically relevant
omplications, including coronary spasm (2.9%) and dissec-
ion, thrombosis, and acute occlusion (0.4%) (32). The
omplication rate appears to be highest in patients with
nstable angina or acute MI (2.9%), as compared with
atients with stable angina pectoris and asymptomatic
atients (0.8 and 0.4%, respectively; p  0.01). In an era of
ignificant improvements in procedural safety (33), this
imitation may assume greater significance in future analysis
f the relative merits of IVUS-guided stent implantation.
NATOMIC VERSUS PHYSIOLOGIC PARAMETERS
O DETERMINE OPTIMAL STENT IMPLANTATION
n alternative to contrast angiography and IVUS for the
etermination of optimal stent deployment is measurement
f fractional flow reserve (FFR). This is defined as the
aximum blood flow to the myocardium achieved in the
resence of a narrowing, compared with the theoretical
aximum blood flow possible in the absence of a narrowing.
t is a physiologic parameter that is an easily obtainable,
ccurate, and lesion-specific index of the functional severity
f coronary stenosis, and it has been correlated with a variety
f conventional noninvasive tests of myocardial ischemia in
atients with intermediate coronary lesions (34–37). Con-
ersely, it has been proposed that after optimal stent
eployment, no hyperemic gradient should persist across the
reated segment.
The FFR index has been compared with IVUS as a
easure of optimal stent deployment (38). An FFR 0.94
as retrospectively defined by receiver-operating character-
stics curve analysis as the physiologic measure of optimal
tent deployment; this corresponds exactly to the lower limit
f the normal range, as found in earlier studies. Concor-
ance between both techniques was present in 91% of all
bservations, and the investigators concluded that the use-
ulness of coronary pressure measurement to guide stent
mplantation was comparable to IVUS. However, a second
tudy that compared FFR after stent implantation with
tandard IVUS criteria for optimal stent deployment con-
luded that an FFR 0.96, measured after stent deploy-
ent, predicts suboptimal results, based on these aforemen-ioned, validated IVUS criteria, but that an FFR0.96 does
ot reliably predict optimal stent results (39). However,
nterpretation of these results is confounded by a number of
imitations, including the use of intracoronary (vs. intrave-
ous) adenosine and the absence of a slow pullback across
he diseased segment to exclude significant (but angio-
raphically undetected) stenoses occurring outside the
tented segment. Furthermore, the results of both studies
hould be interpreted in the context of concerns regarding
he sensitivity of FFR to detect subtle differences in distal
oronary pressure that fall within the normal range, as is the
ase after stent deployment.
Coronary pressure measurement and the FFR index have
lso been correlated with the incidence of adverse events
fter both balloon angioplasty and stent implantation. Bech
t al. (40) evaluated pressure-derived myocardial FFR in 60
atients after conventional balloon angioplasty and con-
luded that in patients with a residual percent diameter
tenosis 35% and FFR 0.90, the clinical outcome up to
wo years is excellent and significantly better than in those
atients in whom the angiographic or functional result, or
oth, were suboptimal (88  6% vs. 59  9%, p  0.014).
imilarly, in a multicenter registry, Pijls et al. (41) investi-
ated the relationship between optimal stent implantation
FFR) and outcome at six months. A post-stent FFR0.90
as associated with a low rate of the composite end point of
eath, MI, or TVR at six months (28 [5.5%] of 507
atients), compared with an incidence of 10.2% for the total
tudy population (final FFR range 0.75 to 1.00). The lowest
vent rate (4.9%) was seen in patients in whom the FFR
ecame normalized (FFR 0.96) after stent implantation.
hese findings are at least comparable with published
stimates of major adverse cardiac events after IVUS-guided
oronary stent implantation. For example, the OPTICUS
nvestigators reported a six-month incidence of the com-
osite end point of death, MI, or TVR of 14.3% in the
VUS arm of this randomized, controlled trial (29).
There are obvious problems with making the aforemen-
ioned comparisons between the results of randomized,
ontrolled trials and a multicenter registry, and these find-
ngs should be regarded as provocative and hypothesis-
enerating, but not definitive proof of the relative merits of
ither treatment strategy. First, there is no definitive evi-
ence (randomized, controlled trial) that adjunctive mea-
urement of post-stent FFR results in improved clinical
utcomes compared with standard angiography-guided
CI. Second, it might be argued that IVUS-guided stent
mplantation is the “gold standard,” and that a direct
omparison of this strategy with an FFR-guided strategy is
ecessary. Finally, it should be remembered that coronary
ressure measurement, in contrast to IVUS, does not elucidate
he cause of suboptimal stent deployment. It is reasonable to
onclude that, in some cases, these two diagnostic modalities
re complementary and not mutually exclusive.
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IVUS Guidance of PCI April 21, 2004:1335–42RUG-ELUTING STENTS:
IMITING IN-STENT RESTENOSIS
he reported differences in IVUS- versus angiography-
uided coronary stent implantation in the CRUISE study
nd the TULIP trial were driven by differences in the
ncidence of TVR (23,30). The results of the SIRIUS (A
ulticenter, Randomized, Double-Blind Study of the
irolimus-Coated BX Velocity Balloon-Expandable Stent
n the Treatment of Patients With De Novo Coronary
rtery Lesions) and TAXUS (A Randomized, Double-
lind Trial to Assess TAXUS Paclitaxel-Eluting Coronary
tents, Slow-Release Formulation in the Treatment of
igh Risk De Novo Coronary Lesions) trials have demon-
trated dramatic reductions in the incidence of in-stent
estenosis after implantation of rapamycin- and paclitaxel-
oated stents, respectively, and this now further undermines
he clinical applicability of the reduction in the incidence of
VR seen when IVUS guidance of bare-metal stent proce-
ures is performed (42).
However, IVUS continues to provide important insights
nto the effects of DES on neointimal proliferation and
ascular healing. For example, it has been suggested that the
nhibition of neointimal proliferation after implantation of a
ES, perhaps exacerbated by post-procedural positive re-
odeling, may result in late stent malapposition that ex-
eeds the background incidence of this finding after bare-
etal stent implantation (43). This was noted in the IVUS
ubstudy of the RAndomized study with the sirolimus-
luting VElocity balloon-expandable stent in the treatment
f patients with de novo native coronary artery Lesions
RAVEL) trial (44), which identified a 21% incidence of
ate stent malapposition in the sirolimus group, but was not
ssociated with stent thrombosis or other adverse clinical
equelae in this trial. More recently, further concerns
egarding the incidence of subacute closure after DES
mplantation have been raised, prompting the U.S. Food
nd Drug Administration to issue a public health web
otification (45). However, an increase in the incidence of
ubacute thrombosis has not been a consistent finding in
ither the treatment arms of the various randomized,
ontrolled trials of sirolimus or paclitaxel DES or published
ata from observational registries (46–48). Nevertheless,
his controversy has prompted many to urge particular
ttention to optimizing the procedural technique with DES
mplantation; for this, IVUS is exceedingly valuable (49).
Similarly, IVUS has provided insight into the morpho-
ogic patterns and possible causes of restenosis after
irolimus-eluting stent implantation. Lemos et al. (50)
nalyzed the angiograms (and IVUS studies, if available) of
9 patients (20 lesions) who had angiographic evidence of
estenosis after implantation of a sirolimus-eluting stent
percent diameter stenosis 50%). Edge restenosis was
requently associated with local trauma outside the stent,
nd in-stent restenosis was commonly focal and occurred in
ssociation with an area of discontinuity with the DES. The duthors concluded that TVR in patients after implantation
f a sirolimus-eluting stent was most likely to be the result
f local factors and not related to intrinsic drug resistance,
nformation which is likely to influence future developments
n stent design, polymer and drug pharmacokinetics, and
tent implantation techniques.
NICHE” INTERVENTIONAL APPLICATIONS OF IVUS
Niche” IVUS applications have been described. Left main
oronary stenoses are notoriously difficult to characterize,
nd IVUS may be useful in accurately defining the cross-
ectional area. There is no consensus regarding the cross-
ectional area at which the left main obstruction is consid-
red critical, but a stenosis area 50% or an absolute area
9 mm2 has been proposed (51). Similarly, FFR has been
sed as an adjunct to contrast angiography in this complex
roup of patients (52).
Transplant coronary artery disease may be particularly
ifficult to characterize using contrast angiography alone,
ecause it is a diffuse process, and there is no true “normal”
eference segment. Therefore, IVUS is useful for the iden-
ification of intimal thickening (0.5 mm)—the hallmark
f transplant vasculopathy—and serial ultrasound surveil-
ance studies have demonstrated an association between the
everity of transplant vasculopathy and clinical outcomes
53).
Intravascular ultrasound has also been widely utilized to
haracterize eccentric plaque and to plan debulking proce-
ures. Studies have clearly demonstrated that contrast an-
iography does not accurately identify the distribution of
laque, and that IVUS is more accurate at guiding selective
laque removal (atherectomy) (54). Similarly, differentiating
etween superficial (intimal) and deep calcium deposits may
e important when planning debulking procedures: rota-
ional atherectomy is most appropriate when calcification is
uperficial, thus facilitating differential cutting (55). Direc-
ional atherectomy may be impossible in this group of
atients (superficial calcification) but is most appropriate for
ccentric lesions, with or without deep calcification (56,57).
Future challenges in the field of interventional cardiology
nclude characterization of vulnerable plaque. A number of
VUS studies have attempted to characterize the appearance
f lipid-laden plaque—the atherosclerotic lesion thought to
e at greatest risk of rupture, thus exposing the highly
hrombogenic components of the subendothelium and lipid
ore and initiating coronary thrombosis. Studies have com-
ared the ultrasound appearance of plaques to histologic
tudies of freshly explanted human arteries (58). Lipid-
aden lesions appear hypoechoic; fibromuscular lesions gen-
rate low-intensity echoes; and fibrous or calcified tissues
re relatively echogenic. However, although IVUS is cer-
ainly accurate in determining the thickness and echogenic-
ty of vessel wall structures, these findings do not consis-
ently correlate with tissue histology, and alternative
iagnostic modalities may prove to be superior to even
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ulnerable plaque (59).
ONCLUSIONS
ntravascular ultrasound has played an integral role in the
volution of interventional cardiology. Specifically, IVUS
as demonstrated the effects of balloon angioplasty and
elped to elucidate the mechanisms of both vessel injury and
ealing. Similarly, the problem of stent thrombosis was
argely solved by clinical evaluation of IVUS-guided, high-
ressure stent deployment and dual, oral antiplatelet ther-
py, and the mechanisms of in-stent restenosis were dem-
nstrated by serial IVUS examinations—insights that have
ontributed to the development of intracoronary brachy-
herapy and DES. There is every reason to believe that
VUS will continue to play a critical role in the development
f interventional techniques and provide further insights
nto the pathophysiology of coronary artery disease; IVUS
uidance of DES implantation may be of particular impor-
ance. However, routine IVUS guidance of coronary stent
mplantation is not supported by this critical reappraisal of
he available evidence, and the safety, efficacy, and effective-
ess of this imaging technology should be taken into
ccount when considering the goals, risks, benefits, and
lternatives to such a treatment strategy.
eprint requests and correspondence: Dr. David R. Holmes,
ardiovascular Diseases and Internal Medicine, Mayo Clinic, 200
irst Street SW, Rochester, Minnesota 55905. E-mail: dholmes@
ayo.edu.
EFERENCES
1. Topol EJ, Nissen SE. Our preoccupation with coronary luminology:
the dissociation between clinical and angiographic findings in ischemic
heart disease. Circulation 1995;92:2333–42.
2. Tobis JM, Mallery JA, Gessert J, et al. Intravascular ultrasound
cross-sectional arterial imaging before and after balloon angioplasty in
vitro. Circulation 1989;80:873–82.
3. Tobis JM, Mallery JA, Mahon D, et al. Intravascular ultrasound
imaging of human coronary arteries in vivo: analysis of tissue charac-
terizations with comparison to in vitro histological specimens. Circu-
lation 1991;83:913–26.
4. Potkin BN, Keren G, Mintz GS, et al. Arterial responses to balloon
coronary angioplasty: an intravascular ultrasound study. J Am Coll
Cardiol 1992;20:942–51.
5. Jain SP, Jain A, Collins TJ, Ramee SR, White CJ. Predictors of
restenosis: a morphometric and quantitative evaluation by intravascular
ultrasound. Am Heart J 1994;128:664–73.
6. Suarez de Lezo J, Romero M, Medina A, et al. Intracoronary
ultrasound assessment of directional coronary atherectomy: immediate
and follow-up findings. J Am Coll Cardiol 1993;21:298–307.
7. Mintz GS, Potkin BN, Keren G, et al. Intravascular ultrasound
evaluation of the effect of rotational atherectomy in obstructive
atherosclerotic coronary artery disease. Circulation 1992;86:1383–93.
8. Laskey WK, Brady ST, Kussmaul WG, et al. Intravascular ultrasono-
graphic assessment of the results of coronary artery stenting. Am
Heart J 1993;125:1576–83.
9. Serruys PW, de Jaegere P, Kiemeneij F, et al., the Benestent Study
Group. A comparison of balloon-expandable-stent implantation with
balloon angioplasty in patients with coronary artery disease. N Engl
J Med 1994;331:489–95.0. Fischman DL, Leon MB, Baim DS, et al., the Stent Restenosis Study
Investigators. A randomized comparison of coronary-stent placement
and balloon angioplasty in the treatment of coronary artery disease.
N Engl J Med 1994;331:496–501.
1. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without
anticoagulation accomplished with intravascular ultrasound guidance.
Circulation 1995;91:1676–88.
2. Goods CM, Al-Shaibi KF, Yadav SS, et al. Utilization of the coronary
balloon-expandable coil stent without anticoagulation or intravascular
ultrasound. Circulation 1996;93:1803–8.
3. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent
implantation without ultrasound guidance and with replacement of
conventional anticoagulation by antiplatelet therapy: 30-day clinical
outcome of the French Multicenter Registry. Circulation 1996;94:
1519–27.
4. Mintz GS, Popma JJ, Hong MK, et al. Intravascular ultrasound to
discern device-specific effects and mechanisms of restenosis. Am J
Cardiol 1996;78:18–22.
5. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mecha-
nisms of in-stent restenosis: a serial intravascular ultrasound study.
Circulation 1996;94:1247–54.
6. Waksman R. Drug-eluting stents: from bench to bed. Cardiovasc
Radiat Med 2002;3:226–41.
7. Frey AW, Hodgson JM, Muller C, Bestehorn HP, Roskamm H.
Ultrasound-guided strategy for provisional stenting with focal balloon
combination catheter. Circulation 2000;102:2497–502.
8. Schiele F, Meneveau N, Gilard M, et al. Intravascular ultrasound-
guided balloon angioplasty compared with stent: immediate and
6-month results of the multicenter, randomized Balloon Equivalent to
STent (BEST) study. Circulation 2003;107:545–51.
9. Laskey WK, Williams DO, Vlachos HA, et al. Changes in the practice
of percutaneous coronary intervention: a comparison of enrollment
waves in the National Heart, Lung, and Blood Institute (NHLBI)
Dynamic Registry. Am J Cardiol 2001;87:964–9.
0. Blasini R, Neumann FJ, Schmitt C, Bokenkamp J, Schomig A.
Comparison of angiography and intravascular ultrasound for the
assessment of lumen size after coronary stent placement: impact of
dilation pressures. Cathet Cardiovasc Diagn 1997;42:113–9.
1. de Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived
from post-stent-implantation intravascular ultrasound predictors of
6-month expected restenosis on quantitative coronary angiography.
Circulation 1999;100:1777–83.
2. de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-
guided optimized stent deployment: immediate and 6-months clinical
and angiographic results from the Multicenter Ultrasound Stenting in
Coronaries (MUSIC) study. Eur Heart J 1998;19:1214–23.
3. Fitzgerald PJ, Oshima A, Hayase M, et al. Final results of the Can
Routine Ultrasound Influence Stent Expansion (CRUISE) study.
Circulation 2000;102:523–30.
4. Albiero R, Rau T, Schluter M, et al. Comparison of immediate and
intermediate-term results of intravascular ultrasound versus angiography-
guided Palmaz-Schatz stent implantation in matched lesions. Circulation
1997;96:2997–3005.
5. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without
anticoagulation accomplished with intravascular ultrasound guidance.
Circulation 1995;91:1676–88.
6. Schiele F, Meneveau N, Vuillemenot A, et al., the REStenosis after
IVUS-guided STenting (RESIST) Study Group. Impact of intravas-
cular ultrasound guidance in stent deployment on 6-month restenosis
rate: a multicenter, randomized study comparing two strategies—with
and without intravascular ultrasound guidance. J Am Coll Cardiol
1998;32:320–8.
7. Schiele F, Meneveau N, Seronde MF, et al. Medical costs of
intravascular ultrasound optimization of stent deployment: results of
the multicenter randomized REStenosis after Intravascular ultrasound
STenting (RESIST) study. Int J Cardiovasc Intervent 2000;3:207–13.
8. Russo RJ, Attubato MJ, Davidson CJ, et al. Angiography versus
intravascular ultrasound-directed stent placement: final results from
AVID (abstr). Circulation 1999;100 Suppl I:I234.
9. Mudra H, di Mario C, de Jaegere P, et al. Randomized comparison of
coronary stent implantation under ultrasound or angiographic guid-
ance to reduce stent restenosis (OPTICUS study). Circulation 2001;
104:1343–9.
33
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
1342 Orford et al. JACC Vol. 43, No. 8, 2004
IVUS Guidance of PCI April 21, 2004:1335–420. Oemrawsingh PV, Mintz GS, Schalij MJ, Zwinderman AH, Jukema
JW, van der Wall EE. Intravascular ultrasound guidance improves
angiographic and clinical outcome of stent implantation for long
coronary artery stenoses: final results of a randomized comparison with
angiographic guidance (TULIP study). Circulation 2003;107:62–7.
1. Nicosia A, van der Giessen WJ, Airiian SG, von Birgelen C, de Feyter
PJ, Serruys PW. Is intravascular ultrasound after coronary stenting a
safe procedure? Three cases of stent damage attributable to ICUS in a
tantalum coil stent. Cathet Cardiovasc Diagn 1997;40:265–70.
2. Hausmann D, Erbel R, Alibelli-Chemarin MJ, et al. The safety of
intracoronary ultrasound: a multicenter survey of 2,207 examinations.
Circulation 1995;91:623–30.
3. Popma JJ, Kuntz RE, Baim DS. A decade of improvement in the
clinical outcomes of percutaneous coronary intervention for multivessel
coronary artery disease. Circulation 2002;106:1592–4.
4. De Bruyne B, Bartunek J, Sys SU, Heyndrickx G. Relation between
myocardial fractional flow reserve calculated from coronary pressure
measurements and exercise-induced myocardial ischemia. Circulation
1995;92:3183–93.
5. Pijls NH, De Bruyne B, Peels KH, et al. Measurement of fractional
flow reserve to assess the functional severity of coronary artery stenoses.
N Engl J Med 1996;334:1703–8.
6. Bartunek J, Marwick TH, Rodrigues ACT, et al. Dobutamine-
induced wall motion abnormalities: correlations with myocardial frac-
tional flow reserve and quantitative coronary angiography. J Am Coll
Cardiol 1996;27:1429–36.
7. Chamuleau SAJ, Meuwissen M, van Eck-Smit BLF, et al. Fractional
flow reserve: absolute and relative coronary blood flow velocity reserve
in relation to the results of technetium-99m sestamibi single-photon
emission computed tomography in patients with two-vessel coronary
artery disease. J Am Coll Cardiol 2001;37:1316–22.
8. Hanekamp CEE, Koolen JJ, Pijls NH, Michels HR, Bonnier HJ.
Comparison of quantitative coronary angiography, intravascular ultra-
sound, and coronary pressure measurement to assess optimum stent
deployment. Circulation 1999;99:1015–21.
9. Fearon WF, Luna J, Samady H, et al. Fractional flow reserve
compared with intravascular ultrasound guidance for optimizing stent
deployment. Circulation 2001;104:1917–22.
0. Bech GJ, Pijls NH, de Bruyne B, et al. Usefulness of fractional flow
reserve to predict clinical outcome after balloon angioplasty. Circula-
tion 1999;99:883–8.
1. Pijls NH, Klauss V, Siebert U, et al. Coronary pressure measurement
after stenting predicts adverse events at follow-up: a multicenter
registry. Circulation 2002;105:2950–4.
2. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology.
Drug-eluting stents: part II. Circulation 2003;107:2383–9.
3. Shah VM, Mintz GS, Apple S, Weissman NJ. Background incidence
of late malapposition after bare-metal stent implantation. Circulation
2002;106:1753–5.
4. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound
findings in the multicenter, randomized, double-blind RAVEL (RAn-
domized study with the sirolimus-eluting VElocity balloon-
expandable stent in the treatment of patients with de novo native
coronary artery Lesions) trial. Circulation 2002;106:798–803.5. U.S. Food and Drug Administration. Cordis Corporation issues a
health care professional letter regarding the CYPHER stent. FDA
News: July 8, 2003. Available at: www.fda.gov/bbs/topics/NEWS/
2003/NEW00919.html. Accessed December 8, 2003.
6. Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces
in-stent intimal hyperplasia in human coronary arteries: a serial
volumetric intravascular ultrasound analysis from the ASian Paclitaxel-
Eluting stent Clinical Trial (ASPECT). Circulation 2003;107:517–
20.
7. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the
treatment of in-stent restenosis: a quantitative coronary angiography
and three-dimensional intravascular ultrasound study. Circulation
2003;107:24–7.
8. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after
sirolimus-eluting stent implantation in patients with acute coronary
syndromes: insights from the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll
Cardiol 2003;41:2093–9.
9. King SB. Restenosis: the mouse that roared. Circulation 2003;108:
248–9.
0. Lemos PA, Saia F, Lighart JMR, et al. Coronary restenosis after
sirolimus-eluting stent implantation: morphological description and
mechanistic analysis from a consecutive series of cases. Circulation
2003;108:257–60.
1. Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological
insights and current clinical applications. Circulation 2001;103:604–
16.
2. Bech GJ, Droste H, Pijls NH, et al. Value of fractional flow reserve in
making decisions about bypass surgery for equivocal left main coronary
artery disease. Heart 2001;86:547–52.
3. Mehra MR, Ventura HO, Stapleton DD. Presence of severe intimal
thickening by intravascular ultrasonography predicts cardiac events in
cardiac allograft vasculopathy. J Heart Lung Transplant 1995;14:
632–9.
4. Mintz GS, Popma JJ, Pichard AD, et al. Limitations of angiography
in the assessment of plaque distribution in coronary artery disease: a
systematic study of target lesion eccentricity in 1,446 lesions. Circu-
lation 1996;93:924–31.
5. Kovach JA, Mintz GS, Pichard AD, et al. Sequential intravascular
ultrasound characterization of the mechanisms of rotational atherec-
tomy and adjunct balloon angioplasty. J Am Coll Cardiol 1993;22:
1024–32.
6. Matar FA, Mintz GS, Pinnow E, et al. Multivariate predictors of
intravascular ultrasound end points after directional coronary atherec-
tomy. J Am Coll Cardiol 1995;25:318–24.
7. Tsuchikane E, Sumitsuji S, Awata N, et al. Final results of the STent
versus directional coronary Atherectomy Randomized Trial (START).
J Am Coll Cardiol 1999;34:1050–7.
8. Nishimura RA, Edwards WD, Warnes CA, et al. Intravascular
ultrasound imaging: in vitro validation and pathologic correlation.
J Am Coll Cardiol 1990;16:145–54.
9. MacNeill BD, Lowe HC, Takano M, Fuster V, Jang IK. Intravascular
modalities for detection of vulnerable plaque: current status. Arterio-
scler Thromb Vasc Biol 2003;23:1333–42.
